Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration

NCT02980458 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Bioequivalence

Interventions

DRUG: Deferiprone 500Mg Tablet
DRUG: Deferiprone 500 MG Oral Tablet [Ferriprox]

Sponsor

SocraTec R&D GmbH

Collaborators

[object Object]